MedTrace Logo

Acupoint Application for Chemotherapy-Induced Nausea and Vomiting in Lung Cancer

NCT07768124 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-08-17

No results posted yet for this study

Summary

This single-center, randomized, controlled study evaluates whether acupoint application added to standard 5-HT3 receptor antagonist anti-nausea medication improves control of chemotherapy-induced nausea and vomiting in adults with lung cancer receiving first-line platinum-based chemotherapy. Participants will be randomly assigned to receive either acupoint application plus a 5-HT3 receptor antagonist or the 5-HT3 receptor antagonist alone for one chemotherapy cycle. The study will compare complete control of delayed nausea and vomiting between the two groups.

Conditions

  • Lung Cancer (Diagnosis)Chemotherapy-Induced Nausea and Vomiting

Interventions

DRUG

5-HT3 receptor antagonist (e.g., ondansetron)

Standard antiemetic prophylaxis for chemotherapy-induced nausea and vomiting.

OTHER

Acupoint application

Herbal plaster applied to selected acupoints to alleviate chemotherapy-induced nausea and vomiting.

Sponsors & Collaborators

  • Xiu Huang

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-15
Primary Completion
2026-10-15
Completion
2026-10-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07768124 on ClinicalTrials.gov